TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Negative water balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Uptake of the HPV vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Primary pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smear positive tuberculosis case notification rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in influenza antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in Thrombocyte function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in Insomnia Symptoms Following Online CBT
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in Sleep Quality Following Online CBT
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Treatment Acceptability at the End of the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of pain in abduction and flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of parturients ingesting clear fluid during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: One month exclusive breastfeeding rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on the Amsterdam IADL Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of malignancy risk factors present
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Life Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Diagnostic Criteria, Severity, and Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of SN-38 and its metabolites relative to serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of tumor in the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Fever
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (plasma concentrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reperfusion rate (mTICI≥2b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combination of clinical and microbial treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine Toxicology for Opiate Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High antibody titer against influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perception of beneficial effect of treatment X
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of oxygenation index (PaO2/FiO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Side effects in the BM-MSCs treatment group
Endpoint domain: Adverse events/effects
Primary endpoint: TNF-α level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aqueous Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: modified Medical Research Council (mMRC) score (breathlessness)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: embryonic development kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of distribution (VT) (KOR binding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Lesion filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life in heart failure patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recurrence of anterior vaginal wall prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: macroscopic healing of the fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter entrapment
Endpoint domain: Adverse events/effects
Primary endpoint: Palliative benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: affective disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Afatinib in Combination With Herceptin(R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S1PR1 levels in PBLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Achieving ACR50 and PASI100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of urethral length measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Initial phone call to arrange mental health treatment appointment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Esophageal stenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Days alive at home
Endpoint domain: Mortality/survival
Primary endpoint: Lumbar tactile acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left and right ventricular volumes and ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Canagliflozin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity of Preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of Intraocular Lens (IOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum trough levels at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Clinical Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain structural MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Variation in the IL28B rs12979860 SNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in short physical performance battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sclerostin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Volume Loss Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric specimen tissue resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric specimen volume resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correction of severe anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Death Before Discharge Home by Day 90
Endpoint domain: Mortality/survival
Primary endpoint: Count of Participants Prescribed Antidepressant Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Concentration (Cmax) of Unbound S-Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator Free Days (VFD) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of patients in Neuro + and Neuro- groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Survival at One Year Post-Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Graft Survival at One Year Post-Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: 24 Hour Fluid Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 24-hour urine collection parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain level at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome-modified Rankin Scale at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in colon polyp burden by number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in colon polyp burden by staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV/HCV risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of SSP-004184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Without Recurrence of Diverticulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in activity index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bladder-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of the appearance of normal bladder epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in gastrointestinal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone Level Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasmatic concentration of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasmatic concentration of Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung mechanics and gas exchange parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentration of contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self Selected Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in target to background ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Glycemic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Maternal Participants Who Achieve 48 Hours of Pregnancy Prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Adherence to Study Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of rabies virus neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC of Cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Cilostazol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glx/Total Creatine Levels in Dorsal Anterior Cingulate Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Posterior Insula Glx/Total Creatine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Indices derived from carbon dioxide (CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal lower back muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of successful nTMS treatment sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analytical performance of calprotectin and CLSM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BMD at L2-L4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: microarchitectural composition of bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean difference in radial smile lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Target Area Hair Count (TAHC) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Self-Assessment (SSA) Score in Hair Growth at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in % BSA psoriasis involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effect on platelet aggregation against PAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effect on inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect on endothelial function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Each Event Category of First Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of postpartum hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of the lymphatic endothelial marker D2-40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Contraceptive Intention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microbial Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in Fitzpatrick Wrinkle and Elastosis Scale (FWS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse Event Rate and Duration
Endpoint domain: Adverse events/effects
Primary endpoint: durable engraftment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unsuccessful Divert placement
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm Occlusion Grading: MRRC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability as assessed by changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic profile of cenderitide (AUC, Cmax, Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic response as assessed by changes in blood pressure and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of collected oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of subjects discharged from hospital and alive at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Discontinued Because of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tablet disintegration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Urinary Incontinent Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Reversal of Anticoagulant Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician perception of formula use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day point-prevalence abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5% lower weight from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: freedom from syncope
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine related high
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline regional oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reducing perioperative mortality in congestive heart failure for non-cardiac surgeries
Endpoint domain: Mortality/survival
Primary endpoint: status at last follow up
Endpoint domain: Mortality/survival
Primary endpoint: Brain Glucose Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain Acetoacetate Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic Accuracy for Coronary Artery Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: long-term effectiveness of pulmonary veins isolation (PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: detection of fusion and pseudo-fusion beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of daily physical activity and its intensity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: differentiation of AVRT and AVNRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Utilities of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve from Time Zero to end of dosing interval (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of arthritis or lupus associated with ICIs
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of skin reactions to radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in BPI-SF Interference Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Women Who Came With Their Partners and Received Couple Counseling and Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Best-corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes